Cover Image
市場調查報告書

卵巢癌:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析

Ovarian cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365174
出版日期 內容資訊 英文 239 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
卵巢癌:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析 Ovarian cancer: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年03月01日 內容資訊: 英文 239 Pages
簡介

本報告提供卵巢癌治療藥市場相關調查分析,提供您市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:卵巢癌

  • 摘要整理
  • 市場概要·趨勢
  • 手法·市場定義
  • Avastin (bevacizumab)
  • Lynparza (olaparib)
  • Niraparib
  • Perjeta (pertuzumab)
  • Recentin (cediranib)
  • Rucaparib
  • Vigil (FANG vaccine)
  • 1次調查手法

治療:卵巢癌

  • 摘要整理
  • 1次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 目前治療選擇
  • 未滿足需求

流行病學:美國·日本·EU5個國家的卵巢癌

  • 摘要整理
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點

上市藥:卵巢癌

  • 摘要整理
  • 產品概要
  • 產品簡介:Avastin
  • 產品簡介:Lynparza

開發平台:卵巢癌

  • 摘要整理
  • 臨床實驗平台概要
  • 初期階段的機會
  • 最近中止開發的藥
  • 標靶藥物簡介
  • 產品簡介 (後期):Perjeta
  • 產品簡介 (後期):Recentin
  • 產品簡介 (後期):Vigil
  • 產品簡介 (後期):binimetinib
  • 產品簡介 (後期):niraparib
  • 產品簡介 (後期):rucaparib

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5652

The ovarian cancer market is poised for growth, which will be driven by increasing incidence of the disease, newly approved therapies, and Lynparza's label expansions.

This report addresses the following questions:

  • What is the overall market potential for Lynparza in ovarian cancer patients?
  • What impact will bevacizumab biosimilars have on Avastin's market share after the expiration of its key patents?
  • How will PARP inhibitors rucaparib and niraparib compete against Lynparza in BRCA-mutated patients?
  • Which pipeline drugs will seek to address the unmet need of treating platinum-resistant advanced ovarian cancer patients?

TABLE OF CONTENTS

FORECAST: OVARIAN CANCER

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Methodology and Market Definition
  • 4. Avastin (bevacizumab)
  • 5. Lynparza (olaparib)
  • 6. Niraparib
  • 7. Perjeta (pertuzumab)
  • 8. Recentin (cediranib)
  • 9. Rucaparib
  • 10. Vigil (FANG vaccine)
  • 11. Primary Research Methodology

TREATMENT: OVARIAN CANCER

  • 12. Executive Summary
  • 13. Primary Research Methodology
  • 14. Disease Definition and Diagnosis
  • 15. Patient Segmentation
  • 16. Current Treatment Options
  • 17. Unmet Needs in Ovarian Cancer

EPIDEMIOLOGY: OVARIAN CANCER IN THE US, JAPAN, AND 5EU

  • 18. Executive Summary
  • 19. Sources and Methodology
  • 20. Forecast
  • 21. Epidemiologist Insight
  • 22. Strengths and Limitations

MARKETED DRUGS: OVARIAN CANCER

  • 23. Executive Summary
  • 24. Product Overview
  • 25. Product profile: Avastin
  • 26. Product profile: Lynparza

PIPELINE: OVARIAN CANCER

  • 27. Executive Summary
  • 28. Clinical Pipeline Overview
  • 29. Early-Phase Opportunities
  • 30. Recently Discontinued Drugs
  • 31. Target Product Profile
  • 32. Product profile (late stage): Perjeta
  • 33. Product profile (late stage): Recentin
  • 34. Product profile (late stage): Vigil
  • 35. Product profile (late stage): binimetinib
  • 36.Product profile (late stage): niraparib
  • 37. Product profile (late stage): rucaparib
Back to Top